民眾中文攝護腺癌專業系列-5『轉移性去勢抵抗性攝護腺癌』的最新治療 (翻譯NCCN攝護腺癌指南2023第一版)

 

蔣智宏1,2洪健華2黃昭淵2

1臺北榮民總醫院員山分院 泌尿外科

2臺灣大學附設醫院 泌尿部

 

Public Chinese Prostate Cancer Professional Series-3Updated Treatment for metastatic Castration-Resistant Prostate Cancer (mCRPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

Chih-Hung Chiang1,2Jian‑Hua Hong2Chao‑Yuan Huang2

1 Department of Urology, Taipei Veterans General Hospital, Yuan-Shan Branch

2 Departments of Urology, National Taiwan University Hospital

 

PurposeThere are few specialized Chinese series on prostate cancer (PCa). This article is completely translated into Chinese according to the NCCN PCa Guideline Version 1. 2023. It is hoped that through the clear and easy-to-understand professional Chinese PCa series introduction, patients and their families can get the most correct and complete understanding from accurate biopsy diagnosis to the latest PCa treatment methods.

Materials and MethodsThis section, metastatic Castration-Resistant Prostate Cancer (mCRPC), is translated from the NCCN PCa Guidelines Versions 1. 2023.

ResultsAndrogen Deprivation Therapy (ADT) to maintain castration level of testosterone <50 ng/dL is the essential treatment for mCRPC. For patients with mCRPC who have not received new hormonal agents (NHA), Chemotherapy (docetaxel, cabazitaxel($))NHA(abiraterone/enzalutamide) or Radium-223 (Only bone metastasis mCRPC) are the recommended treatment options. For patients with mCRPC who have received NHA but not Chemotherapy, Chemotherapy (docetaxel, cabazitaxel($))Poly (ADP-ribose) polymerases (PARPs) inhibitor ($) (Olaparib) or Radium-223 (Only bone metastasis mCRPC) are the recommended treatment options. For patients with mCRPC who have received NHA and Chemotherapy, Chemotherapy (cabazitaxel($))177Lu-PSMA-617($)PARPs inhibitor ($)(Olaparib) or Radium-223 (Only bone metastasis mCRPC) are the recommended treatment options. Hospice careto help and take care of mCRPC patients with respect as well as to alleviate their pain in the fiinal stage of PCa.

ConclusionObjective detailed clinical evaluation and adequate communication are the key to the treatment selection of "metastatic Castration- Resistant PCa".

    位置
    資料夾名稱
    摘要
    發表人
    陳佳能
    單位
    台灣泌尿科醫學會
    建立
    2023-07-05 16:14:17
    最近修訂
    2023-07-05 16:15:03
    更多